These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33778733)

  • 21. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CT texture analysis in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: A potential imaging biomarker for treatment response and prognosis.
    Chee CG; Kim YH; Lee KH; Lee YJ; Park JH; Lee HS; Ahn S; Kim B
    PLoS One; 2017; 12(8):e0182883. PubMed ID: 28797063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study.
    Meng Q; Zhao J; Yu Y; Wang K; Ren J; Xu C; Wang Y; Wang G
    BMC Cancer; 2023 Feb; 23(1):191. PubMed ID: 36849918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of Inflammatory Breast Cancer Survival Outcomes Using Computed Tomography-Based Texture Analysis.
    Song SE; Seo BK; Cho KR; Woo OH; Ganeshan B; Kim ES; Cha J
    Front Bioeng Biotechnol; 2021; 9():695305. PubMed ID: 34354986
    [No Abstract]   [Full Text] [Related]  

  • 26. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
    Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CT Textural Analysis of Large Primary Renal Cell Carcinomas: Pretreatment Tumor Heterogeneity Correlates With Histologic Findings and Clinical Outcomes.
    Lubner MG; Stabo N; Abel EJ; Del Rio AM; Pickhardt PJ
    AJR Am J Roentgenol; 2016 Jul; 207(1):96-105. PubMed ID: 27145377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative Prediction of BRAF Mutation Status in Colorectal Cancer Using a Clinical-radiomics Model.
    Xue T; Peng H; Chen Q; Li M; Duan S; Feng F
    Acad Radiol; 2022 Sep; 29(9):1298-1307. PubMed ID: 35033450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.
    Chaddad A; Sabri S; Niazi T; Abdulkarim B
    Med Biol Eng Comput; 2018 Dec; 56(12):2287-2300. PubMed ID: 29915951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
    Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CT texture analysis as a predictor of favorable response to anti-PD1 monoclonal antibodies in metastatic skin melanoma.
    Bonnin A; Durot C; Barat M; Djelouah M; Grange F; Mulé S; Soyer P; Hoeffel C
    Diagn Interv Imaging; 2022 Feb; 103(2):97-102. PubMed ID: 34666945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring CT Texture Parameters as Predictive and Response Imaging Biomarkers of Survival in Patients With Metastatic Melanoma Treated With PD-1 Inhibitor Nivolumab: A Pilot Study Using a Delta-Radiomics Approach.
    Guerrisi A; Russillo M; Loi E; Ganeshan B; Ungania S; Desiderio F; Bruzzaniti V; Falcone I; Renna D; Ferraresi V; Caterino M; Solivetti FM; Cognetti F; Morrone A
    Front Oncol; 2021; 11():704607. PubMed ID: 34692481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
    Hegewisch-Becker S; Nöpel-Dünnebacke S; Hinke A; Graeven U; Reinacher-Schick A; Hertel J; Lerchenmüller CA; Killing B; Depenbusch R; Al-Batran SE; Lange T; Dietrich G; Tannapfel A; Arnold D
    Eur J Cancer; 2018 Sep; 101():105-113. PubMed ID: 30036739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy.
    Yip C; Landau D; Kozarski R; Ganeshan B; Thomas R; Michaelidou A; Goh V
    Radiology; 2014 Jan; 270(1):141-8. PubMed ID: 23985274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
    Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
    JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
    Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
    Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virtual monoenergetic imaging in rapid kVp-switching dual-energy CT (DECT) of the abdomen: impact on CT texture analysis.
    Baliyan V; Kordbacheh H; Parameswaran B; Ganeshan B; Sahani D; Kambadakone A
    Abdom Radiol (NY); 2018 Oct; 43(10):2693-2701. PubMed ID: 29541830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer.
    Guo TA; Wu YC; Tan C; Jin YT; Sheng WQ; Cai SJ; Liu FQ; Xu Y
    Int J Cancer; 2019 Sep; 145(6):1625-1634. PubMed ID: 31162857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Class 1, 2, and 3
    Schirripa M; Biason P; Lonardi S; Pella N; Pino MS; Urbano F; Antoniotti C; Cremolini C; Corallo S; Pietrantonio F; Gelsomino F; Cascinu S; Orlandi A; Munari G; Malapelle U; Saggio S; Fontanini G; Rugge M; Mescoli C; Lazzi S; Reggiani Bonetti L; Lanza G; Dei Tos AP; De Maglio G; Martini M; Bergamo F; Zagonel V; Loupakis F; Fassan M
    Clin Cancer Res; 2019 Jul; 25(13):3954-3961. PubMed ID: 30967421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
    Tie J; Gibbs P; Lipton L; Christie M; Jorissen RN; Burgess AW; Croxford M; Jones I; Langland R; Kosmider S; McKay D; Bollag G; Nolop K; Sieber OM; Desai J
    Int J Cancer; 2011 May; 128(9):2075-84. PubMed ID: 20635392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.